Acrivon Therapeutics, Inc. Quarterly Operating Lease, Right-of-Use Asset in USD from Q4 2021 to Q2 2024

Taxonomy & unit
us-gaap: USD
Description
Amount of lessee's right to use underlying asset under operating lease.
Summary
Acrivon Therapeutics, Inc. quarterly Operating Lease, Right-of-Use Asset history and growth rate from Q4 2021 to Q2 2024.
  • Acrivon Therapeutics, Inc. Operating Lease, Right-of-Use Asset for the quarter ending June 30, 2024 was $3.98M, a 9.31% decline year-over-year.
Operating Lease, Right-of-Use Asset, Quarterly (USD)
Operating Lease, Right-of-Use Asset, YoY Quarterly Growth (%)
Period Value YoY Chg Change % Date Report Filed
Q2 2024 $3.98M -$408K -9.31% Jun 30, 2024 10-Q 2024-08-13
Q1 2024 $4.21M -$374K -8.17% Mar 31, 2024 10-Q 2024-05-14
Q4 2023 $4.43M -$341K -7.15% Dec 31, 2023 10-Q 2024-08-13
Q3 2023 $4.19M -$772K -15.6% Sep 30, 2023 10-Q 2023-11-09
Q2 2023 $4.38M Jun 30, 2023 10-Q 2023-08-11
Q1 2023 $4.58M Mar 31, 2023 10-Q 2023-05-09
Q4 2022 $4.77M -$731K -13.3% Dec 31, 2022 10-K 2024-03-28
Q3 2022 $4.96M Sep 30, 2022 10-Q 2022-12-15
Q4 2021 $5.5M Dec 31, 2021 10-K 2023-03-28
* An asterisk sign (*) next to the value indicates that the value is likely invalid.